LONDON – 22 October 2024: Sano Genetics, the UK-based precision medicine company accelerating precision medicine clinical trials, has been named as one of Bloomberg’s Startups to Watch 2024. This latest recognition highlights the business’s significant growth and impact improving access to clinical trials and precision medicine.
Bloomberg’s Startups to Watch is an annual list that identifies the 25 UK-based startups that represent the diversity and innovation of the country’s startup ecosystem. Eligible businesses are assessed according to several criteria including the scope of the problem they tackle, the creativity of their ideas, their traction with investors and customers, and their commitment to diversity.
Founded in 2017 by three Cambridge PhD students, Sano Genetics offers a platform that combines patient recruitment, genetic testing, analytics, and long-term patient engagement in one place. This approach radically improves clinical trials, enabling precision medicine teams to move up to 10x faster, reduce costs by up to 55% and, most importantly, achieve breakthroughs for patients.
Sano was featured alongside Wayve, Cleo, and CuspAI in Bloomberg's list, a selection – in Bloomberg’s own words – of “companies that are growing fast, working on something truly unique and come from a diverse group of founders”.
The company has recently secured flagship partnerships in the US and launched projects aimed at enhancing patient access to clinical trials and advancing precision medicine across the UK. These initiatives contribute significantly to the broader healthcare landscape by facilitating more inclusive and efficient research which ultimately help to create lifesaving treatments in the near term.
Charlotte Guzzo, Co-Founder and Chief Operating Officer, Sano Genetics, comments: "Sano Genetics was founded on the belief that contributing to clinical research should be engaging, supportive, and meaningful for participants. This recognition is a testament to our talented team and unwavering dedication to accelerating the global transition to precision medicine with a tech-forward and patient-centric approach."
About Sano Genetics
Sano Genetics’ broad mission is to accelerate the world’s transition to precision medicine. Although accessibility to DNA sequencing has surged in the past decade, precision medicine studies have failed to keep up. They are still complex, time-consuming and costly, and many potentially life-changing treatments never see daylight. Sano simplifies precision medicine studies with a 360° platform that connects every stage: strategy consultation, patient finding, biomarker screening, patient engagement and analytics. The company works with pharmaceutical companies and biotechs to find, screen, and engage participants faster and more cost effectively; with researchers to increase efficiency and impact; and with patient advocacy groups to drive research with and for their communities. Headquartered in Cambridge, UK, Sano’s diverse team combines years of expertise in medical research, genetics and security-focused software engineering.
More information is available at https://www.sanogenetics.com.
.png)
